skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

15319

Long-acting β2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety



Review

(9214) Total Article Views


Authors: Andrea Rossi, Sonia Khirani, Mario Cazzola

Published Date July 2008 Volume 2008:3(4) Pages 521 - 529
DOI: http://dx.doi.org/10.2147/COPD.S1353

Andrea Rossi1, Sonia Khirani1, Mario Cazzola2

1Unit of Respiratory Diseases, Hospital of Bergamo, Bergamo, Italy; 2Unit of Respiratory Diseases, Department of Internal Medicine, University of Rome ‘Tor Vergata’, Rome, Italy

Abstract: COPD is characterized by progressive airflow obstruction which does not fully reverse to inhaled or oral pharmacotherapy. The management of patients with COPD has taken a totally new direction over the past 20 years, thank to the use of novel therapies aimed to improve and modify the natural history of COPD. Long-acting bronchodilators, including long-acting β2-agonists (LABAs), were introduced several years ago in order to enhance improvements in lung function, health status related quality of life, and reduce the rate of exacerbations. These effects can be boosted by the combination of LABAs with long-acting anticholinergic, and/or with inhaled corticosteroids. Inhaled LABAs are commonly well tolerated although adverse effects such as tremor and palpitations are occasionally troublesome.

Keywords: LABA, COPD, efficacy, safety




Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter


Readers of this article also read:

  • Journal Indexing

    See where all the Dove Press journals are indexed.

  • Testimonials

    "I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University.

  • MLA'14 -

    May 16–21, 2014
    Chicago

  • ERS Int'l Congress

    6 - 10 September, 2014
    Munich, Germany

  • CHEST 2014

    25 - 30 October, 2014
    Austin, Texas